Gilead Receives US FDA Approval to Begin Clinical Trials of Inhaled Version of Remdesivir
|
By HospiMedica International staff writers Posted on 23 Jun 2020 |
|
Illustration
Gilead Sciences, Inc. (Foster City, CA, USA) has received the go-ahead from the US Food and Drug Administration (FDA Silver Spring, MD, USA) to begin trials of an inhaled version of its antiviral drug remdesivir in patients with COVID-19.
Remdesivir is presently being used to treat patients through emergency use authorizations and other access programs around the world. Currently, remdesivir is given to COVID-19 patients intravenously through daily infusions in the hospital. So far, randomized controlled trials of remdesivir have been evaluating its safety and efficacy in hospitalized patients. Data from these studies shows that remdesivir has the potential to be of meaningful benefit to patients with COVID-19.
As part of its next wave of clinical development, Gilead aims to study remdesivir in treating earlier in the disease, in combination with other therapies and in additional patient groups. The inhaled formulation studies are one means of exploring the use of remdesivir in the earlier stages of COVID-19. Gilead has begun screening healthy volunteers for Phase 1 trials for the inhaled version of its investigational antiviral medicine in COVID-19 patients to be conducted in August. An inhaled formulation would be given through a nebulizer, which could potentially allow for easier administration outside the hospital, at earlier stages of the disease which could help stem the tide of the pandemic.
“Without years of research on remdesivir, we would not have been able to move so quickly in response to this outbreak,” said Daniel O’Day, Chairman and CEO, Gilead Sciences, in an open letter. “We were able to rapidly enter into clinical trials because we already had sufficient knowledge from studying remdesivir in other viruses to hope it might work against COVID-19. Our commitment to remdesivir will continue now as we explore its full potential in the hope of helping many more patients with COVID-19.”
Related Links:
Gilead Sciences, Inc.
US Food and Drug Administration (FDA)
Remdesivir is presently being used to treat patients through emergency use authorizations and other access programs around the world. Currently, remdesivir is given to COVID-19 patients intravenously through daily infusions in the hospital. So far, randomized controlled trials of remdesivir have been evaluating its safety and efficacy in hospitalized patients. Data from these studies shows that remdesivir has the potential to be of meaningful benefit to patients with COVID-19.
As part of its next wave of clinical development, Gilead aims to study remdesivir in treating earlier in the disease, in combination with other therapies and in additional patient groups. The inhaled formulation studies are one means of exploring the use of remdesivir in the earlier stages of COVID-19. Gilead has begun screening healthy volunteers for Phase 1 trials for the inhaled version of its investigational antiviral medicine in COVID-19 patients to be conducted in August. An inhaled formulation would be given through a nebulizer, which could potentially allow for easier administration outside the hospital, at earlier stages of the disease which could help stem the tide of the pandemic.
“Without years of research on remdesivir, we would not have been able to move so quickly in response to this outbreak,” said Daniel O’Day, Chairman and CEO, Gilead Sciences, in an open letter. “We were able to rapidly enter into clinical trials because we already had sufficient knowledge from studying remdesivir in other viruses to hope it might work against COVID-19. Our commitment to remdesivir will continue now as we explore its full potential in the hope of helping many more patients with COVID-19.”
Related Links:
Gilead Sciences, Inc.
US Food and Drug Administration (FDA)
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Wound Irrigation Solution
Prontosan®
New
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channel
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read more
New AI Approach Monitors Brain Health Using Passive Wearable Data
Brain health spans cognitive and emotional functions and can fluctuate even in adults without diagnosed disease. Detecting early changes remains difficult in routine care and burdens specialty services... Read more
Critical Care
view channel
Automated IV Labeling Solution Improves Infusion Safety and Efficiency
Medication administration in high-acuity settings is often complicated by multiple concurrent infusions, making accurate line identification essential. In a 10-hospital intensive care unit study, 60% of... Read more
First-Of-Its-Kind AI Tool Detects Pulmonary Hypertension from Standard ECGs
Pulmonary hypertension is a progressive, life‑threatening disease that is frequently missed early because symptoms such as dyspnea are nonspecific and diagnostic delays can exceed two years.... Read more
Surgical Techniques
view channel
Continuous Monitoring with Wearables Enhances Postoperative Patient Safety
Postoperative hypoxemia on general surgical wards is common and often missed by intermittent vital sign checks. Undetected low oxygen levels can delay recovery and raise the risk of complications that... Read more
New Approach Enables Customized Muscle Tissue Without Biomaterial Scaffolds
Volumetric muscle loss is a traumatic loss of skeletal muscle that often leads to permanent functional impairment and limited reconstructive options. Current experimental strategies struggle to deliver... Read more
Patient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Health IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Business
view channel
GE HealthCare Leads Major European Initiative to Advance Cardio-Oncology Care
Cardiovascular complications are increasingly recognized among people undergoing or recovering from cancer treatment, driven by pre‑existing disease and the cardiotoxic effects of chemotherapy, radiotherapy,... Read more
